Abbott India Limited (ABBOTINDIA) AI Stock Analysis

• Market Cap: ₹657.63B
• Dividend Yield: 1.54%
• Average Volume (3M): 579.00
• Price to Earnings (P/E): 45.3
• Beta (1Y): 0.66
• Revenue Growth: 11.17%
• EPS Growth: 17.22%
• Country: IN
• Employees: 3,814
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 172.30
• Shares Outstanding: 21,249,302
• 10 Day Avg. Volume: 697
• 30 Day Avg. Volume: 579
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹35,025.00
• Price Target Upside: 13.27% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 62 Neutral
• Price Target: ₹33,050.00 ▲(6.88% Upside)

Abbott India's strong financial performance is the most significant factor, reflecting robust profitability and a solid balance sheet. However, technical analysis indicates bearish momentum, and the valuation suggests the stock may be overvalued, which tempers the overall score.

Abbott India Limited Business Overview & Revenue Model

Company Description

Abbott India Limited operates as a pharmaceutical company in India. It offers pharmaceutical products for various therapeutic areas, such as women's health, gastroenterology, metabolic, central nervous system, pain management, pre-term labor, vitamins, insomnia, vaccines, consumer health, etc. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. Abbott India Limited was incorporated in 1944 and is headquartered in Mumbai, India. Abbott India Limited is a subsidiary of Abbott Capital India Limited.

How the Company Makes Money

Abbott India Limited generates revenue primarily through the sale of its pharmaceutical products and healthcare solutions. The company's revenue streams include prescription medications, over-the-counter products, and specialized healthcare solutions targeted at hospitals and healthcare providers. Key factors contributing to its earnings include its extensive product portfolio, strong brand presence, and strategic partnerships with healthcare institutions and professionals. Additionally, Abbott India's focus on research and development, along with its ability to adapt to market demands, plays a significant role in sustaining its revenue growth.

Abbott India Limited Financial Statement Overview

Summary

Abbott India Limited demonstrates strong financial health across income, balance sheet, and cash flow verticals. The company exhibits robust profitability, efficient asset utilization, and solid cash flow management, positioning it well for continued growth. The balance sheet is a particular strength due to low leverage and solid equity foundation.

Income Statement

Abbott India Limited showcases strong profitability with consistent revenue growth and robust margins. The gross profit margin has remained healthy, reflecting efficient cost management. Net profit margin has improved significantly, indicating strong bottom-line performance. EBIT and EBITDA margins also reflect operational efficiency, contributing to the positive outlook in this vertical.

Balance Sheet

The company maintains a solid balance sheet with a low debt-to-equity ratio, indicating prudent financial leverage. The equity ratio is strong, showcasing a substantial proportion of assets financed by equity, enhancing financial stability. The return on equity remains impressive, reflecting effective utilization of shareholder funds.

Cash Flow

Abbott India exhibits strong cash flow management with consistent free cash flow generation. While there is a slight decline in operating cash flow, the company maintains a healthy free cash flow to net income ratio, indicating efficient cash conversion. The free cash flow growth rate, although slightly volatile, remains positive, supporting future investments and shareholder returns.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	64.09B	64.09B	58.47B	53.47B	49.10B	43.08B
Gross Profit	27.33B	29.12B	26.14B	23.61B	22.42B	19.07B
EBITDA	19.70B	19.70B	16.98B	13.56B	11.61B	9.98B
Net Income	14.14B	14.14B	12.01B	9.49B	7.99B	6.91B
Balance Sheet
Total Assets	59.17B	59.17B	51.93B	45.56B	42.24B	38.40B
Cash, Cash Equivalents and Short-Term Investments	34.09B	34.09B	21.18B	19.22B	27.35B	23.98B
Total Debt	1.97B	1.97B	832.30M	1.13B	1.52B	1.53B
Total Liabilities	16.84B	16.84B	14.95B	13.67B	14.04B	12.38B
Stockholders Equity	42.33B	42.33B	36.99B	31.89B	28.20B	26.02B
Cash Flow
Free Cash Flow	0.00	9.59B	11.64B	8.59B	9.04B	7.03B
Operating Cash Flow	0.00	10.12B	12.13B	8.93B	9.48B	7.27B
Investing Cash Flow	0.00	1.82B	-5.60B	-1.48B	-3.96B	-718.20M
Financing Cash Flow	0.00	-9.25B	-7.45B	-6.39B	-6.37B	-5.82B

Abbott India Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 30922.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ABBOTINDIA, the sentiment is Negative. The current price of 30922.65 is below the 20-day moving average (MA) of 31499.73, below the 50-day MA of 32731.44, and above the 200-day MA of 30359.74, indicating a neutral trend. The MACD of -507.69 indicates Positive momentum. The RSI at 39.58 is Neutral, neither overbought nor oversold. The STOCH value of 24.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ABBOTINDIA.

Abbott India Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	76 Outperform	636.70B	18.77	10.68%	0.35%	7.76%	-2.84%
LUPIN	72 Outperform	927.74B	25.05	19.08%	0.59%	12.40%	63.16%
ZYDUSLIFE	72 Outperform	1.04T	22.77	18.89%	1.05%	14.52%	9.46%
BIOCON	68 Neutral	472.92B	110.57	4.68%	0.14%	6.80%	-75.66%
GLAXO	66 Neutral	463.41B	48.77	47.54%	1.96%	6.65%	48.47%
ABBOTINDIA	62 Neutral	₹657.63B	45.28		1.54%	11.17%	17.22%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%